UK – Stivarga final NICE recommendation for hepatocellular carcinoma

Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer.

Stivarga (regorafenib) is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had Nexavar (sorafenib), but only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

This means they are fully active and able to carry on all pre-disease performance without restriction or they are restricted in physically strenuous activity but able to carry out work of a light or sedentary nature.

According to NICE, a few hundred patients each year will benefit from the decision, which marks a turnaround from a guidance published earlier in the year which rejected the drug…